Anika Therapeutics (ANIK) Cost of Revenue (2010 - 2026)
Anika Therapeutics (ANIK) posted quarterly Cost of Revenue of $11.4 million for Q2 2026, down 17.97% year-over-year from $13.9 million in Q2 2025, and up 7.07% quarter-over-quarter from $10.6 million in Q1 2026.
Anika Therapeutics (ANIK) Cost of Revenue (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has reported Cost of Revenue for 17 consecutive years, with $11.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Cost of Revenue fell 17.97% year-over-year to $11.4 million; the TTM figure through Jun 2026 stood at $45.6 million (down 6.78% YoY), while the FY2025 annual figure was $49.0 million, up 11.62% from the prior year.
- Cost of Revenue rose to $11.4 million in Q2 2026 per ANIK's latest filing, from $10.6 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $17.5 million in Q3 2022 and bottomed at -$8.7 million in Q4 2023.
- Historically, Cost of Revenue has averaged $10.8 million across 5 years, with a median of $11.9 million in 2025.
- Annual changes were most pronounced in 2022 — Cost of Revenue tumbled 137.1% — and 2024, when it surged 255.4%.
- Anika Therapeutics' Cost of Revenue stood at -$6.6 million in 2022, then plunged by 32.15% to -$8.7 million in 2023, then soared by 255.4% to $13.5 million in 2024, then fell by 15.14% to $11.4 million in 2025, then slipped by 0.61% to $11.4 million in 2026.
- Business Quant data shows ANIK's Cost of Revenue at $11.4 million in Q2 2026, $10.6 million in Q1 2026, and $11.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Anika Therapeutics | 285.86 Mn | 247.45 Mn | 21.24 Mn | 11.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.37 Mn |
| Jun 30, 2026 | 11.37 Mn |
| Mar 31, 2026 | 10.62 Mn |
| Mar 31, 2026 | 10.62 Mn |
| Dec 31, 2025 | 11.44 Mn |
| Dec 31, 2025 | 11.44 Mn |
| Sep 30, 2025 | 12.23 Mn |
| Sep 30, 2025 | 12.23 Mn |
| Jun 30, 2025 | 13.86 Mn |
| Jun 30, 2025 | 13.86 Mn |
| Mar 31, 2025 | 11.49 Mn |
| Mar 31, 2025 | 11.49 Mn |
| Dec 31, 2024 | 13.48 Mn |
| Dec 31, 2024 | 13.48 Mn |
| Sep 30, 2024 | 10.15 Mn |
| Sep 30, 2024 | 10.15 Mn |
| Jun 30, 2024 | 10.24 Mn |
| Jun 30, 2024 | 10.24 Mn |
| Mar 31, 2024 | 10.05 Mn |
| Mar 31, 2024 | 10.05 Mn |